Partnering with Tzu

Tzu offers 3 models for pharma partners​

01

Improving early drug
evaluation

We generate target expression data in pre-treated, actively metastasizing disease.

This allows for the identification and the validation of novel, more relevant, new targets.

​

02

Improving early clinical evaluation of new therapies

We can measure target expression and resistance in early clinical evaluation.

Discriminate between SOC and experimental treatments earlier and make better decisions.

03

Patient stratification in late stage trials and label expansions (diagnostics)

Our CTC target expression analysis can identify target expression correlation with overall response rates​.

Stratification based on CTC target expression could improve overall response rates in pre-selected cohorts.​

send Mike an email

CONTACT

Talk to our CBO

Partnership conversations are led by Dr. Mike Shaw, Chief Business Officer at Tzu Cancer Therapeutics.